GH · NASDAQ · STOCK
Guardant Health (GH) Stock Analysis
$167.38
52W $61.00 – $191.05
50/100
$22.47B
-48.0
1.58
Is GH Bullish or Bearish?
Mixed.
Innellis AI committee rates Guardant Health, Inc. (GH) Watch with a composite score of 50/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +10.17 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -9.83 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 7.18) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 42.7% YoY -- genuine top-line momentum — Growth
- News sentiment is positive (+0.20 across 20 articles, 14d) — News
Bear Case
- Price-to-book of 20.7x prices in significant intangible value — Value
- ROE of only -246.6% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 7.18 adds balance-sheet risk to the value case — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 7.18) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
50/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 96%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 20.7x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 42.7% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 7.18) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 20 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 51.6 to 49.8.
- Conviction changed from moderate to contested.
- Committee agreement fell notably from 67% to 50%.
- Bullish support removed: 3 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Technical Analyst: stance bullish->neutral; score 61->48 (-13).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
39.9
Neutral
MACD Histogram
-1.797
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$154.09
Resistance
$176.15
Bollinger %B
0.13
Inside Bands
Price vs Moving Averages
EMA 9
$172.13
Below
EMA 21
$172.34
Below
EMA 50
$166.31
Above
EMA 200
$131.65
Above
Fundamental Analysis
Valuation
67
Growth
31
Profitability
50
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-48.0×
P/B Ratio
-99.25×
PEG Ratio
10.88
Dividend Yield
0.00%
52W High
$191.05
52W Low
$61.00
Quality & Growth
ROE
41918.2%
ROA
-2067.3%
Gross Margin
6501.2%
Operating Margin
-3974.8%
Revenue Growth YoY
—
Debt / Equity
-7.61
AI Fundamental Assessment
P/E ratio of -48.0 (inexpensive relative to a 15-40x range); Price-to-book of -99.2x; PEG ratio of 10.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 419.2%; Return on assets of -20.7%; Net margin of -38.3%; Gross margin of 65.0%; Current ratio of 4.03 (healthy short-term liquidity); Debt-to-equity of -7.61; Free cash flow per share is negative (-1.82); Most recent quarter missed estimates by 0.0%; EPS growth decelerating (+55.0% -> +6.7% QoQ); Analyst estimates rising over recent quarters
Get the Full GH Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →